Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 4, 2004, Pages 324-330

  Hiraoka, Haruhiko ^b   Yamamoto, Koujirou ^b   Okano, Nobuhiro ^b   Morita, Toshihiro ^b   Goto, Fumio ^b   Horiuchi, Ryuya ^a  

^a GUNMA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM; PROPOFOL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; DIALYSIS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG INFUSION; ERYTHROCYTE; FEMALE; HEPATIC VEIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RADIAL ARTERY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANESTHETICS, INTRAVENOUS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROBABILITY; PROPOFOL; PROSPECTIVE STUDIES; PROTEIN BINDING; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 1842637373     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.004     Document Type: Article

References (37)

1. du Souich P., Verges J., Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet. 24:1993;435-440.
2. Wilkinson G.R., Shand D.G. Commentary a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 18:1975;377-390.
3. Dhillon S., Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 13:1982;553-560.
4. Orr J.M., Abbott F.S., Farrell K., Ferguson S., Sheppard I., Godolphin W. Interaction between valproic acid and aspirin in epileptic children serum protein binding and metabolic effects. Clin Pharmacol Ther. 31:1982;642-649.
5. Monks A., Richens A. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther. 27:1980;89-95.
6. Olsen G.D., Bennett W.M., Porter G.A. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther. 17:1975;677-684.
7. Chalon S.A., Desager J.P., Desante K.A., Frye R.F., Witcher J., Long A.J., et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther. 73:2003;178-191.
8. Ermer J.C., Boni J.P., Cevallos W.H., DeCleene S., Burghart P., Rudnick M.R., et al. Bromfenac disposition in patients with impaired kidney function. Clin Pharmacol Ther. 61:1997;312-318.
9. Miller R.S., Peterson G.M., McLean S., Moller C. Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. J Clin Pharm Ther. 22:1997;197-205.
10. Hynynen M., Siltanen T., Sahlman A., Pohjasvaara T., Muck W., Kaste M. Continuous infusion of nimodipine during coronary artery surgery haemodynamic and pharmacokinetic study. Br J Anaesth. 74:1995;526-533.
11. Hynynen M., Hynninen M., Soini H., Neuvonen P.J., Heinonen J. Plasma concentration and protein binding of alfentanil during high-dose infusion for cardiac surgery. Br J Anaesth. 72:1994;571-576.
12. Finegan B.A., Hussain M.D., Tam Y.K. Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. Ther Drug Monit. 14:1992;485-492.
13. Morgan D.J., Crankshaw D.P., Prideaux P.R., Chan H.N., Boyd M.D. Thiopentone levels during cardiopulmonary bypass. Changes in plasma protein binding during continuous infusion. Anaesthesia. 41:1986;4-10.
14. Shand DG, Mitchell JR, Oates JA. Pharmacokinetic drug interactions. In: Concepts in biochemical pharmacology handbook of experimental pharmacology. Vol. 23, part 3, chapter 69. New York: Springer-Verlag; 1975. p. 272-314.
15. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 71:2002;115-121.
16. MacKichan J.J. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet. 16:1989;65-73.
17. Rolan P.E. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol. 37:1994;125-128.
18. Sansom L.N., Evans A.M. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 12:1995;227-233.
19. Serlin M.J., Mossman S., Sibeon R.G., Tempero K.F., Breckenridge A.M. Interaction between diflunisal and warfarin. Clin Pharmacol Ther. 28:1980;493-498.
20. Stoeckel K., Trueb V., Dubach U.C., McNamara P.J. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol. 34:1988;151-156.
21. Evans G.H., Nies A.S., Shand D.G. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 186:1973;114-122.
22. Cockshott I.D., Douglas E.J., Plummer G.F., Simons P.J. The pharmacokinetics of propofol in laboratory animals. Xenobiotica. 22:1992;369-375.
23. Altmayer P., Buch U., Buch H.P. Propofol binding to human blood proteins. Arzneimittelforschung. 45:1995;1053-1056.
24. Mazoit J.X., Samii K. Binding of propofol to blood components implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol. 47:1999;35-42.
25. Shingu K., Osawa M., Mori K. Clinical study of propofol in male volunteers. [in Japanese] Masui. 39:1990;219-229.
26. Gepts E., Camu F., Cockshott I.D., Douglas E.J. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg. 66:1987;1256-1263.
27. Knibbe C.A., Zuideveld K.P., DeJongh J., Kuks P.F., Aarts L.P., Danhof M. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther. 72:2002;670-684.
28. Schuttler J., Ihmsen H. Population pharmacokinetics of propofol a multicenter study. Anesthesiology. 92:2000;727-738.
29. Plummer G.F. Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 421:1987;171-176.
30. Dawidowicz A.L., Fornal E. The advantages of cell lysis before blood sample preparation by extraction for HPLC propofol analysis. Biomed Chromatogr. 14:2000;493-497.
31. Okano N., Hiraoka H., Owada R., Fujita N., Kadoi Y., Saito S., et al. Hepatosplanchnic oxygenation is better preserved during mild hypothermic than during normothermic cardiopulmonary bypass. Can J Anaesth. 48:2001;1011-1014.
32. Hashimoto K., Sasaki T., Hachiya T., Onoguchi K., Takakura H., Oshiumi M., et al. Superior hepatic mitochondrial oxidation-reduction state in normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg. 121:2001;1179-1186.
33. He Y.L., Ueyama H., Tashiro C., Mashimo T., Yoshiya I. Pulmonary disposition of propofol in surgical patients. Anesthesiology. 93:2000;986-991.
34. Shafer S.L., Stanski D.R. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology. 76:1992;327-330.
35. Evans G.H., Shand D.G. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. Clin Pharmacol Ther. 14:1973;494-500.
36. Yoshitani K., Kawaguchi M., Takahashi M., Kitaguchi K., Furuya H. Plasma propofol concentration and EEG burst suppression ratio during normothermic cardiopulmonary bypass. Br J Anaesth. 90:2003;122-126.
37. Bruhn J., Ropcke H., Rehberg B., Bouillon T., Hoeft A. Electroencephalogram approximate entropy correctly classifies the occurrence of burst suppression pattern as increasing anesthetic drug effect. Anesthesiology. 93:2000;981-985.